Poor Applicability of Currently Available Prognostic Scoring Systems for Prediction of Outcome in KIT D816V-Negative Advanced Systemic Mastocytosis

Nicole Naumann,Martina Rudelius,Johannes Lübke,Deborah Christen,Jakob Bresser,Karl Sotlar,Georgia Metzgeroth,Alice Fabarius,Wolf-Karsten Hofmann,Jens Panse,Hans-Peter Horny,Nicholas C. P. Cross,Andreas Reiter,Juliana Schwaab

DOI: https://doi.org/10.3390/cancers16030593

2024-01-31

Cancers

Abstract:Within our nationwide registry, we identified a KIT D816V mutation (KIT D816Vpos.) in 280/299 (94%) patients with advanced systemic mastocytosis (AdvSM). Age, cytopenias and the presence of additional somatic mutations confer inferior overall survival (OS). However, little is known about the characteristics of KIT D816V-negative (D816Vneg.) AdvSM. In 19 D816Vneg. patients, a combination of clinical, morphological and genetic features revealed three subgroups: (a) KIT D816H- or Y-positive SM (KIT D816H/Ypos., n = 7), predominantly presenting as mast cell leukemia (MCL; 6/7 patients), (b) MCL with negative KIT sequencing (KITneg. MCL, n = 7) and (c) KITneg. SM with associated hematologic neoplasm (KITneg. SM-AHN, n = 5). Although >70% of patients in the two MCL cohorts (KIT D816H/Ypos. and KITneg.) were classified as low/intermediate risk according to prognostic scoring systems (PSS), treatment response was poor and median OS was shorter than in a KIT D816Vpos. MCL control cohort (n = 29; 1.7 vs. 0.9 vs. 2.6 years; p < 0.04). The KITneg. SM-AHN phenotype was dominated by the heterogeneous AHN (low mast cell burden, presence of additional mutations) with a better median OS of 4.5 years. We conclude that (i) in MCL, negativity for D816V is a relevant prognostic factor and (ii) PSS fail to correctly classify D816Vneg. patients.

oncology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is the poor applicability of currently available prognostic scoring systems in predicting the outcomes of patients with KIT D816V - negative advanced systemic mastocytosis (AdvSM). Specifically, the study focuses on:

1. **Clinical, morphological and genetic characteristics of KIT D816V - negative patients**: These patients are relatively rare clinically and have limited data, so more detailed description and classification are required.
2. **Effectiveness of existing prognostic scoring systems**: Existing prognostic scoring systems are mainly designed for KIT D816V - positive patients, and it is unclear whether they are applicable to KIT D816V - negative patients.
3. **Treatment response and survival rate**: Evaluate the treatment response and overall survival rate of KIT D816V - negative patients, especially compared with KIT D816V - positive patients.

### Research background
Systemic mastocytosis (SM) is a rare bone marrow tumor, mainly characterized by the accumulation of abnormal mast cells in multiple tissues. Most patients (> 95%) carry the D816V mutation of the KIT gene, while a small number of patients carry other mutations (such as D816H or D816Y) or have no KIT mutation at all. The clinical manifestations and prognostic characteristics of these KIT D816V - negative patients are not yet clear.

### Research objectives
This study aims to:
- **Characterize the clinical, morphological and genetic characteristics of KIT D816V - negative AdvSM patients**, including 7 patients with KIT D816H or D816Y mutations and 12 patients without KIT mutations.
- **Evaluate the applicability of existing prognostic scoring systems in KIT D816V - negative patients** and explore their effectiveness in patient classification.
- **Analyze the treatment response and survival rate of these patients** and compare them with KIT D816V - positive patients.

### Main findings
- **High frequency of MCL phenotype**: Most KIT D816H/Y - positive and KIT - negative patients present with the most malignant subtype - mast cell leukemia (MCL).
- **Limitations of prognostic scoring systems**: Although more than 70% of patients are classified as low/medium - risk according to the existing scoring systems, their treatment response is poor and the median overall survival is also short.
- **Survival differences among different subtypes**: KIT - negative patients with associated hematological neoplasms (AHN) show a better median overall survival (4.5 years), while the median overall survival of KIT D816H/Y - positive and KIT - negative MCL patients is 1.7 years and 0.9 years respectively, which are significantly lower than that of KIT D816V - positive MCL patients (2.6 years).

Through these findings, the study emphasizes the important prognostic significance of the KIT D816V - negative state in MCL and points out the limitations of existing prognostic scoring systems in these patients.